COST-EFFECTIVENESS OF ANTI-BCMA CAR T-CELL THERAPY IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Barnes, J., I [1 ]
Frosch, Z. A. [2 ]
Garfall, A. L. [3 ]
Vogl, D. [3 ]
Lin, J. [3 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Univ Penn, Philadelphia, PA 19104 USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE41
引用
收藏
页码：S343 / S343
页数：1
相关论文
共 50 条
  • [1] Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
    Quintas-Cardama, Alfonso
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (03):
  • [2] Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Yamamoto, Chihiro
    Minakata, Daisuke
    Yokoyama, Daizo
    Furuki, Shuka
    Noguchi, Atsuto
    Koyama, Shunsuke
    Oyama, Takashi
    Murahashi, Rui
    Nakashima, Hirotomo
    Ikeda, Takashi
    Kawaguchi, Shin-ichiro
    Hyodo, Kazuki
    Toda, Yumiko
    Ito, Shoko
    Nagayama, Takashi
    Umino, Kento
    Morita, Kaoru
    Ashizawa, Masahiro
    Ueda, Masuzu
    Hatano, Kaoru
    Sato, Kazuya
    Ohmine, Ken
    Fujiwara, Shin-ichiro
    Kanda, Yoshinobu
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 118.e1 - 118.e15
  • [3] CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
    Cavo, Michele
    HAEMATOLOGICA, 2023, 108 (08) : 1988 - 1990
  • [4] Anti-BCMA CAR T-cell Therapy Reins in Myeloma
    Dolgin, Elie
    CANCER DISCOVERY, 2019, 9 (07) : 817 - 819
  • [5] Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
    Raje, Noopur
    Berdeja, Jesus
    Lin, Yi
    Siegel, David
    Jagannath, Sundar
    Madduri, Deepu
    Liedtke, Michaela
    Rosenblatt, Jacalyn
    Maus, Marcela V.
    Turka, Ashley
    Lam, Lyh-Ping
    Morgan, Richard A.
    Friedman, Kevin
    Massaro, Monica
    Wang, Julie
    Russotti, Greg
    Yang, Zhihong
    Campbell, Timothy
    Hege, Kristen
    Petrocca, Fabio
    Quigley, M. Travis
    Munshi, Nikhil
    Kochenderfer, James N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (18): : 1726 - 1737
  • [6] The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
    Manjunath, Shwetha H.
    Cohen, Adam D.
    Lacey, Simon F.
    Davis, Megan M.
    Garfall, Alfred L.
    Melenhorst, J. Joseph
    Maxwell, Russell
    Arscott, W. Tristram
    Maity, Amit
    Jones, Joshua A.
    Plastaras, John P.
    Stadtmauer, Edward A.
    Levine, Bruce L.
    June, Carl H.
    Milone, Michael C.
    Paydar, Ima
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6580 - 6590
  • [7] Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
    Liang, Zhiyu
    Li, Ping
    Kang, Liqing
    Zhou, Lili
    Xu, Yang
    Ye, Shiguang
    Du, Juan
    Li, Bing
    Wang, Yiwen
    Yu, Lei
    Qian, Wenbin
    Liang, Aibin
    BLOOD ADVANCES, 2022, 6 (01) : 293 - 296
  • [8] Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
    Puertas, Borja
    Mateos, Maria-Victoria
    Gonzalez-Calle, Veronica
    HEMASPHERE, 2022, 6 (03):
  • [9] Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
    Wang, Ying
    Li, Chunrui
    Xia, Jieyun
    Li, Ping
    Cao, Jiang
    Pan, Bin
    Tan, Xu
    Li, Hujun
    Qi, Kunming
    Wang, Xiangmin
    Shi, Ming
    Jing, Guangjun
    Yan, Zhiling
    Cheng, Hai
    Zhu, Feng
    Sun, Haiying
    Sang, Wei
    Li, Depeng
    Zhang, Xi
    Li, Zhenyu
    Zheng, Junnian
    Liang, Aibin
    Zhou, Jianfeng
    Xu, Kailin
    BLOOD ADVANCES, 2021, 5 (23) : 5290 - 5299
  • [10] Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
    D'Agostino, Mattia
    Raje, Noopur
    LEUKEMIA, 2020, 34 (01) : 21 - 34
12345